Caracemide, identified by the CAS number 81424-67-1, is a chemical compound that belongs to the class of amides. It is characterized by its structural features, which include a carbonyl group (C=O) directly bonded to a nitrogen atom (N), typical of amides. This compound is often studied for its potential applications in pharmaceuticals and biochemistry due to its ability to interact with biological systems. Caracemide may exhibit properties such as solubility in polar solvents, stability under various conditions, and the ability to form hydrogen bonds, which can influence its reactivity and interactions with other molecules. Additionally, its specific functional groups may impart unique biological activities, making it a subject of interest in medicinal chemistry. However, detailed information regarding its toxicity, environmental impact, and specific applications may require further investigation and should be referenced from specialized literature or databases for comprehensive understanding.

Caracemide

81424-67-1: (Acetyl-(methylcarbamoyl)amino) N-methylcarbamate, Acetamide, N-((methylamino)carbonyl)-N-((methylamino)carbonyl)oxy)-, Brn 5935912, Caracemida, Caracemida [Spanish], Caracemide [USAN:INN], Caracemidum, Caracemidum [Latin], Ccris 1729, N-((Methylamino)carbonyl)-N-(((methylamino)carbonyl)oxy)acetamide, N-(Methylcarbamoyl)-N-(methylcarbamoyloxy)acetamid, N-(methylcarbamoyl)-N-[(methylcarbamoyl)oxy]acetamide, N-Acetyl-N,O-bis(methylcarbamoyl)hydroxylamine, N-Acetyl-N,O-di(methylcarbamoyl)hydroxylamine, N-Acetyl-N-(methylcarbamoyloxy)-N'-methylurea, Nsc 253272, Unii-H74F6J185A, Caracemide

Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide can be used in anticancer studies.

N-(Methylcarbamoyl)acetamido N-methylcarbamate (NMCA) is a novel anti-cancer compound that selectively binds to the CB2 receptor. NMCA has been shown to inhibit the growth of cancer cells in vitro and in vivo, as well as reduce the size of bowel tumors. It also has a beneficial effect on cardiac function. The mechanism of action is not completely understood, but it may be due to binding to the CB2 receptor and blocking the activation of other receptors such as TNF-α. NMCA can be formulated into biocompatible polymers that are suitable for drug delivery. Furthermore, this compound can be used for treating inflammatory bowel disease and renal cell cancer.

CAS 81424-67-1: Caracemide

Caracemide

Ref: 54-BUP06764

Caracemide

Ref: TM-T14864

N-(Methylcarbamoyl)acetamido N-methylcarbamate

Ref: 3D-GDA42467